Eric Lefkofsky has become one of the most well-known entrepreneurs in the United States today. His ideas on how entrepreneurs can use existing infrastructure to help them build innovative new products have become almost gospel truth among many of today’s leading business personalities. He is also one of the most prolific medical philanthropists in the United States today, having donated tens of millions of dollars of his own money to various charitable causes.
However, many people do not know that, in 2016, Eric Lefkofsky cofounded one of the most ambitious and potentially transformative medical product companies in recent history. Tempus, a start-up dedicated to the application of artificial intelligence to the medical space, promises to bring such innovative technologies as human genome sequencing and electronic medical records into an all-encompassing approach to the treatment of disease and more
Lefkofsky points out that the number of medical records and other data points today are so vast that there are millions of potentially crucial pieces of knowledge that go unnoticed by treating physicians every day. He believes that the incremental understanding that these data points could provide in filling out the general knowledge of doctors across the United States could potentially lead to dramatically improved patient outcomes and effective cures of many different types of diseases.
Lefkofsky believes that there is no place where this approach holds more promise than in the treatment of cancer. After a close family member was diagnosed with cancer, Lefkofsky was shocked to find out, upon accompanying his family member to treatment sessions, that modern oncologists use data that is of poorer quality than that provided to many truck drivers. He decided that great improvements could be made in the way that physicians interact with the data that they have at their disposal.
Through its development of artificial intelligence applications, Lefkofsky believes that Tempus will be able to instantaneously answer questions such as how a patient with a given genetic makeup will likely interact with a given treatment regimen. These insights have the potential to completely revolutionize the way in which patients are treated and the effectiveness those treatments ultimately have.